PDT Partners LLC Takes $3.46 Million Position in Progyny, Inc. (NASDAQ:PGNY)

PDT Partners LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 200,636 shares of the company’s stock, valued at approximately $3,461,000. PDT Partners LLC owned approximately 0.24% of Progyny at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in PGNY. Signaturefd LLC increased its position in shares of Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after buying an additional 1,355 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after buying an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after purchasing an additional 1,526 shares in the last quarter. Caitlin John LLC increased its position in shares of Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock worth $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, Natixis purchased a new stake in shares of Progyny during the fourth quarter worth approximately $69,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on PGNY. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. Bank of America boosted their price target on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Finally, BTIG Research upgraded Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Monday, March 31st. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $23.64.

Progyny Stock Down 0.0 %

Shares of NASDAQ:PGNY opened at $22.75 on Tuesday. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $33.84. The business has a fifty day moving average of $21.92 and a two-hundred day moving average of $19.14. The stock has a market cap of $1.95 billion, a P/E ratio of 39.22, a PEG ratio of 2.39 and a beta of 1.33.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.